The India Advanced Wound Care Market was valued at $108.1 Million in 2025 and projected to reach to $188 Million by 2030, representing a compound annual growth rate of 11.7%. India's advanced wound care market is poised for exceptional growth driven by demographic shifts, rising healthcare spending, and increased awareness of advanced treatment options.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
India's advanced wound care market is expanding at 11.7% CAGR, significantly outpacing the global rate of 7.6%, making it one of the most dynamic markets in the healthcare sector.
Increasing prevalence of diabetes, pressure ulcers, and chronic wounds among India's growing geriatric population is driving demand for advanced wound care solutions and specialized treatment products.
Government initiatives like Ayushman Bharat and improved hospital infrastructure in tier-2 and tier-3 cities are enhancing accessibility to advanced wound care treatments across India.
The market is projected to grow from USD 108.1 million in 2025 to USD 188.0 million by 2030, representing a 73.9% increase in market value over the five-year forecast period.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SUPERABSORBENT DRESSINGS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 7.6% from 2025 to 2030 |
| Largest Segment | HOSPITALS, ASCS, AND WOUND CARE CENTERS (End User) |
| Market Size Base Year (Billions) | ~USD 13.4 (2025) |
| Revenue Forecast (Billions) | ~USD 19.32 (2030) |
| Segments Covered | Product, Type, Wound Type, End User |
4 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOME CARE SETTINGS | 48.8 | 53.8 | 59.4 | 65.7 | 72.8 | 80.8 | 89.8 | 100.1 | 11 |
| HOSPITALS, ASCS, AND WOUND CARE CENTERS | 87.1 | 97.2 | 108.6 | 121.6 | 136.2 | 152.9 | 172 | 193.9 | 12.3 |
| OTHER END USERS | 28.9 | 31.7 | 34.8 | 38.3 | 42.3 | 46.7 | 51.6 | 57.3 | 10.5 |
| TOTAL | 164.7 | 182.6 | 202.8 | 225.6 | 251.3 | 280.4 | 313.4 | 351.4 | 11.6 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Dressings (Foam, Hydrocolloid, Film),NPWT,Debridement Devices, |
| ADVANCED MEDICAL SOLUTIONS | United Kingdom | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film, Alginates),Topical Agents & Infection Control,NPWT, |
| ALLIQUA BIOMEDICAL | United States | Public Company | Foam Dressings,Hydrocolloid Dressings,Film Dressings, |
| HENRY SCHEIN | United States | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film, other),NPWT (Negative Pressure Wound Therapy),Debridement Devices, |
| HILL-ROM HOLDINGS, INC. | United States | Private Company | Dressings (Foam, Hydrocolloid, Film),NPWT,Debridement Devices, |
| MEDIPASS HEALTHCARE LTD | United Kingdom | Foam dressings,Hydrocolloid dressings,Film dressings, | |
| CONMED CORPORATION | United States | Public Company | Dressings (Foam, Hydrocolloid, Film),NPWT,Debridement Devices, |
| SOLVENTUM | United States | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film),Negative Pressure Wound Therapy (NPWT),Debridement Devices, |
| MöLNLYCKE AB | Sweden | Private Company | Foam Dressings,Hydrocolloid Dressings,Film Dressings, |
| CONVATEC GROUP PLC | United Kingdom | Public Company | Foam Dressings,Hydrocolloid Dressings,Film Dressings, |
| ORGANOGENESIS INC. | United States | Public Company | Biological Skin Substitutes,Placental Allografts and ECM Grafts,Topical Agents and Antimicrobial Barriers, |
| PAUL HARTMANN AG | Germany | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film, Hydroactive, Silicone SAP),NPWT,Traditional & Debridement-Adjacency (gauze, sponges, contact layers, basic debridement tools), |
| CARDINAL HEALTH | United States | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film and related),NPWT (devices and disposables),Debridement Devices, |
| MIMEDX GROUP, INC. | United States | Public Company | Biological Skin Substitutes (placental allografts – EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, EPIEFFECT),Surgical and Orthopedic Applications (AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, AMNIOEFFECT),Topical Agents / Adjacent Wound Therapies (REGENKIT WOUND GEL and related), |
| OWENS & MINOR | United States | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film),NPWT (Negative Pressure Wound Therapy),Debridement Devices, |
| ESSITY AKTIEBOLAG | Sweden | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film),NPWT,Debridement Devices, |
| INTEGRA LIFESCIENCES CORPORATION | United States | Public Company | Biological Skin Substitutes,Dressings (Foam, Hydrocolloid, Film),NPWT, |
| AVERY DENNISON CORPORATION | United States | Public Company | Foam Dressings (materials supply),Hydrocolloid Dressings (materials supply),Film Dressings (materials supply), |
| MATIV HOLDINGS, INC. | United States | Public Company | Advanced Dressings (Foam, Hydrocolloid, Film substrates and components),NPWT (consumable interfaces, drapes, and fixation materials),Debridement Devices (supporting materials and packaging), |
Kindred Healthcare Inc. is a United States-based private company founded in 1985 that operates with 64,200 employees. The company provides healthcare services and solutions across multiple care settings.
Advanced Medical Solutions is a United Kingdom-based public company founded in 1991 with 1,800 employees. The company develops and manufactures advanced medical products.
Alliqua Biomedical is a United States-based public company founded in 1997 with 6 employees. The company operates in the biomedical sector.
Henry Schein is a United States-based public company founded in 1932 with 25,000 employees. The company is a distributor of healthcare products and services.
Hill-Rom Holdings, Inc. is a United States-based private company founded in 1915 with 10,000 employees. The company manufactures and distributes medical devices and equipment.
Insufficient data provided for company description.
ConMed Corporation is a United States-based public company founded in 1970 with 3,900 employees. The company develops and manufactures medical devices and equipment.
Solventum is a United States-based public company founded in 2023 with 20,584 employees. The company operates in the healthcare and technology sectors.
Mölnlycke AB is a Swedish private company founded in 1849 with 8,463 employees. The company manufactures and distributes medical products and wound care solutions.
ConvaTec Group PLC is a United Kingdom-based public company founded in 1978 with 10,910 employees. The company develops and manufactures medical products and devices.
Organogenesis Inc. is a United States-based public company with 854 employees. The company develops and manufactures regenerative medicine and advanced wound care products.
Paul Hartmann AG is a German public company founded in 1818 with 10,066 employees. The company manufactures and distributes medical and hygiene products.
Cardinal Health is a United States-based public company founded in 1979 with 55,392 employees. The company is a distributor of pharmaceuticals, medical supplies, and healthcare services.
Mimedx Group, Inc. is a United States-based public company founded in 2006 with 808 employees. The company develops and manufactures regenerative medicine products.
Owens & Minor is a United States-based public company founded in 1882 with 6,500 employees. The company is a distributor of medical and surgical supplies.
Essity Aktiebolag is a Swedish public company founded in 1849 with 36,000 employees. The company manufactures and distributes hygiene and health products.
Integra LifeSciences Corporation is a United States-based public company founded in 1989 with 4,427 employees. The company develops and manufactures medical devices and regenerative medicine products.
Avery Dennison Corporation is a United States-based public company founded in 1935 with 35,000 employees. The company manufactures and distributes labeling and packaging materials.
Mativ Holdings, Inc. is a United States-based public company founded in 1995 with 5,000 employees. The company manufactures specialty materials and engineered products.
India's advanced wound care market was valued at USD 108.1 million in 2025 and is expected to reach USD 188.0 million by 2030.
India's advanced wound care market is projected to grow at a compound annual growth rate (CAGR) of 11.7% from 2025 to 2030.
Key growth drivers in India include rising prevalence of chronic wounds, increasing diabetic and geriatric populations, healthcare infrastructure modernization, and expanding private healthcare networks.
India's 11.7% CAGR significantly outpaces the global advanced wound care market CAGR of 7.6%, indicating faster regional expansion and market opportunity.
India is witnessing increased adoption of foam dressings, hydrogels, antimicrobial wound care solutions, and advanced dressing technologies for chronic wounds and surgical site management.
The study involved major activities in estimating the current market size for the advanced wound care market. Exhaustive secondary research was done to collect information on the advanced wound care industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the advanced wound care market.
The four steps involved in estimating the market size are:
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS)]were referred to identify and collect information for the global advanced wound care market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market & technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various companies and organizations in the advanced wound care market. The primary sources from the demand side include pharmaceutical companies, biotechnology companies, CROs, pharmacies, medical device companies, and research academics and universities. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global advanced wound care market. All the primary service providers were identified at the global and/or country/regional level. Revenue mapping for the key players was done for the respective business segments/subsegments. The global advanced wound care market was split into various segments and subsegments based on:
The above data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
The research methodology used to estimate the market size includes the following:

The total market was split into several segments after arriving at the overall market size by applying the abovementioned process. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Advanced wound care encompasses specialized dressings and therapies to promote optimal wound healing. These may include hydrogels, foams, and alginates, among others. Advanced therapies like negative pressure wound therapy (NPWT) substitutes offer innovative solutions for complex wounds, enhancing healing rates and reducing complications.
Full forecast, segment splits, and company analysis for all Advanced Wound Care Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report